Rallis India Limited · NSE:RALLIS
Rallis India — Q2 FY21 Earnings Presentation
15 slides from Rallis India's earnings presentation, October 2020
Slide 1: Results Presentation Q2 FY21
Results Presentation Q2 FY21 1
Slide 2: Disclaimer
Disclaimer This presentation, except for the historical information, may contain statements, including the words or phrases such as ‘expects, anticipates, intends, will, would, undertakes, aims, estimates, contemplates, seeks to, objective, goal, projects, should’ and similar expressions or variatio
Slide 3: Rallis – Areas of Strength
Rallis – Areas of Strength Well entrenched connect with the Indian farmer Chemistry ● Crop Protection ● Partnering with global (International Plant growth innovators (Domestic ● business) Strong R&D and business) ● ● Nutrients(PGN) executional capabilities ● Soil conditioner ● Environmentally ● Seed
Slide 4: Domestic business
Domestic business Leading Agrochemical Company Presence across value chain: Seeds – Soil Conditioners – Crop Protection Chemicals - Plant Growth Nutrients Market share: ~ 6% (Crop protection & PGN), ~3% (Seeds) Strong & Healthy pipeline of sustainable products Nationwide footprint – more than 3800 d
Slide 5: International Business – Primed for growth
International Business – Primed for growth Alliances Contract Manufacturing • Developing Technicals for global Agro chemicals players • Manufacturing molecules for global chemical players • Key products • Key products - Poly Ether Ketone Ketone(PEKK) & – Pendimethalin: Used as a pre-emergence herbic
Slide 6: Seed business
Seed business Rallis develops, produces and sells hybrid seeds including Paddy, Millet, Maize and Bt Cotton with main exposure (80-85%) to the Kharif season Strong market position - among top 3 in Hybrid Paddy (3rd) & Hybrid Millet (2nd) and Maize (6th). With around a million packets sold, our Bt Co
Slide 7: Strategic Initiatives
Strategic Initiatives Domestic business • Customer connect through digital campaigns • Refresh distribution channel : Add distributors to enhance growth • Higher focus towards digitisation and technology adoption • Increase focus on new product launches; portfolio optimisation • Improve connect betw
Slide 8: Q2 FY21 - Performance Highlights: Overall
Q2 FY21 - Performance Highlights: Overall Rs Crs EBITDA PAT AEI 128 92 120 117 86 83 95 61 FY 20 FY21 FY 20 FY21 Q1 Q2 Q1 Q2 ● CY Qtr Revenue was at Rs. 725 Crs i.e. lower by 3% as compared to PY Q2. ● Company has opted for lower ● % EBIDTA margins are at 16.1%; ● Seeds business has registered growt
Slide 9: Q2 FY21 - Performance Highlights: Crop Care division
Q2 FY21 - Performance Highlights: Crop Care division Rs Cr ● Overall YoY revenue declined by 6% ● Overall drop in EBIDTA due to drop in ● Company has opted for lower tax mainly due to drop in international topline rate at the start of the year business. ● Domestic business grew by ~ 8% YoY ● Price e
Slide 10: Q2 FY21 - Performance Highlights: Seeds Division
Q2 FY21 - Performance Highlights : Seeds Division Rs Cr ● 29% growth in topline in Q2 FY 21 ● Growth is due to Volume and Tax rate at higher level Better Price Realization than PY due to overall ● Volume growth in Maize effective tax rate being at ~ 24% ● Better price realization in Paddy 10 Copyrig
Slide 11: Category-wise Revenue Split Q2 & H1
Category-wise Revenue Split Q2 & H1 Category wise Note: Pl note that these revenue breakups are for Crop Price corrections in Metribuzin impacting Herbicide Protection revenue compared to PY 11 Copyright © Rallis India Limited. All rights reserved.
Slide 12: Revenue Split Domestic/International Q2 & H1
Revenue Split Domestic/International Q2 & H1 Category wise Q2 H1 Note: Drop in Volume of Metribuzin with price correction Pl note that these revenue breakups are for Crop coupled with drop in Contract Manufacturing Volumes Protection leading to overall drop in % share of International revenue 12 Cop
Slide 13: Capex - Update
Capex - Update • Overall Capex implementation impacted due to COVID 19 : delayed by 2- 3 months • Formulation Plant at Dahej, CZ - Phase 1 Expected to be now completed by March 21 • Capacity Expansion of our AI on track. • Board has approved further investments of ~ Rs. 70 Crs for expansion of MPP,
Slide 14: Operational Highlights
Operational Highlights New Product Progress – ❖ Launched 1 formulation in Q2; 2 formulations YTD ❖ Received own registration approval for Metribuzin for USA ❖ Successful launch of Aquafert – Potato, Onion, Vegetable (FNP) and Flobor in Crop Nutrition category Tackling COVID Difficulties and Operatio
Slide 15: Thank You
THANK YOU 15 Copyright © Rallis India Limited. All rights reserved.